Business Description
Polaryx Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US73110F1003
Description
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.71 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -41.08 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 9.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.45 | |||||
Quick Ratio | 3.45 | |||||
Cash Ratio | 3.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -3.77 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -163.12 | |||||
ROA % | -143.07 | |||||
ROIC % | -6951.47 | |||||
ROC (Joel Greenblatt) % | -5194.51 | |||||
ROCE % | -119.04 | |||||
Moat Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 42.64 | |||||
Price-to-Tangible-Book | 44.4 | |||||
EV-to-EBIT | -23.86 | |||||
EV-to-Forward-EBIT | -9.98 | |||||
EV-to-EBITDA | -23.86 | |||||
EV-to-FCF | -21.29 | |||||
| Price-to-Net-Current-Asset-Value | 44.4 | |||||
| Price-to-Net-Cash | 59.2 | |||||
Earnings Yield (Greenblatt) % | -4.19 | |||||
FCF Yield % | -4.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Polaryx Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.114 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 1.776 - 2.37 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Polaryx Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Polaryx Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 138 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 47 days | ||
| First quarter earnings results for 2026 | 2026-05-29 | -- | ||
| the 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 | -- | ||
| Annual report for 2025 | 2026-03-24 | -- |
Show
Entries
Polaryx Therapeutics Inc Frequently Asked Questions
What is Polaryx Therapeutics Inc(FRA:1V8)'s stock price today?
The current price of FRA:1V8 is €1.78. The 52 week high of FRA:1V8 is €2.37 and 52 week low is €1.78.
When is next earnings date of Polaryx Therapeutics Inc(FRA:1V8)?
The next earnings date of Polaryx Therapeutics Inc(FRA:1V8) is 2026-08-31 Est..
Does Polaryx Therapeutics Inc(FRA:1V8) pay dividends? If so, how much?
Polaryx Therapeutics Inc(FRA:1V8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Polaryx Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers